This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
VIGLPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
COO Q2 Earnings Signal Growth and Caution: How to Play the Stock?
by Zacks Equity Research
Cooper Companies beats fiscal second-quarter estimates and raises guidance, but faces fertility headwinds and inventory pressures. Is COO still a long-term growth play?
JNJPositive Net Change ALCNegative Net Change COOPositive Net Change
medical medical-devices
Vivani Stock Gains After Announcing Spin-Off Plans for Cortigent Unit
by Zacks Equity Research
VANI is set to spin off Cortigent, aiming to sharpen its focus on drug implants and unlock long-term value for both entities.
ANGOPositive Net Change CVSPositive Net Change ITGRNegative Net Change VANINegative Net Change
medical medical-devices
Charles River Stock May Gain From Extended CHDI Research Deal on HD
by Zacks Equity Research
CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.
CRLNegative Net Change CORPositive Net Change PAHCPositive Net Change HIMSPositive Net Change
medical medical-devices
Hims & Hers vs. Amwell: Which Telehealth Stock Is the Better Buy?
by Debanjana Dey
HIMS targets personalized, AI-powered care with bold obesity moves, while AMWL bets on system-wide integration via Converge and top-tier health alliances. Who wins? Let's see.
AMWLNegative Net Change HIMSPositive Net Change
medical medical-devices
BD Stock Might See Short-term Decline After Warning on Tamponade Tubes
by Zacks Equity Research
BDX warns of safety risks tied to its esophagogastric balloon tamponade tubes after one death and two injuries, prompting updated usage instructions for clinicians.
ANGOPositive Net Change BDXNegative Net Change CVSPositive Net Change ITGRNegative Net Change
medical medical-devices
Abbott Benefits From Libre & Biosimilars Amid FX, Cost Headwinds
by Zacks Equity Research
ABT sees a 21.6% jump in CGM sales and growing global diagnostics demand, while FX and macro pressure temper its outlook.
ABTPositive Net Change PBHNegative Net Change PAHCPositive Net Change HIMSPositive Net Change
medical medical-devices
Marqeta (MQ) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
MQPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Top 4 Value Stocks With Impressive PEG Ratios to Buy Now
by Urmimala Biswas
Here are the four discounted PEG-based value stocks that qualify our screening criteria- URBN, XRAY, LTM and EXEL.
XRAYPositive Net Change URBNNegative Net Change EXELPositive Net Change LTMNegative Net Change
medical medical-devices retail transportation
COO Q2 Earnings Beat, 2025 Sales Outlook Tightened, Stock Down
by Zacks Equity Research
COO's fiscal Q2 earnings and sales beat market expectations on the back of strong growth. Improvement in operating margin bodes well.
CVSPositive Net Change COOPositive Net Change CORPositive Net Change WGSPositive Net Change
earnings medical medical-devices
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Zacks Equity Research
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
CVSPositive Net Change CORPositive Net Change CODXNegative Net Change WGSPositive Net Change
medical medical-devices
Is the Options Market Predicting a Spike in Integra LifeSciences Stock?
by Zacks Equity Research
Investors need to pay close attention to Integra LifeSciences stock based on the movements in the options market lately.
IARTNegative Net Change
medical medical-devices
Thermo Fisher Launches New Spectral Flow Cytometer: Stock to Gain?
by Zacks Equity Research
TMO unveils spectral-enabled Attune Xenith Flow Cytometer to streamline workflows and boost research accuracy.
TMOPositive Net Change PBHNegative Net Change PAHCPositive Net Change HIMSPositive Net Change
medical medical-devices
Here's Why You Should Add HealthEquity Stock to Your Portfolio Now
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
ANGOPositive Net Change CVSPositive Net Change HQYPositive Net Change ITGRNegative Net Change
medical medical-devices
VEEV Stock Up as Q1 Earnings & Revenues Beat Estimates, Margin Rise
by Zacks Equity Research
Veeva Systems' fiscal first-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.
ANGOPositive Net Change CVSPositive Net Change VEEVPositive Net Change ITGRNegative Net Change
earnings medical medical-devices
Coeur Mining (CDE) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
CDEPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Ouster, Inc. (OUST) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
OUSTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
United Microelectronics Corporation (UMC) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
UMCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Reasons to Retain The Cooper Companies Stock in Your Portfolio Now
by Zacks Equity Research
COO benefits from the strength in its business segments. Its acquisitions are likely to drive the top line. However, a rise in selling, general and administrative expenses is concerning.
CVSPositive Net Change COOPositive Net Change CORPositive Net Change WGSPositive Net Change
medical medical-devices
ISRG vs. MDT: Which Robotic Surgery Stock Is a Smarter Buy Now?
by Indrajit Bandyopadhyay
Intuitive Surgical or Medtronic -- who leads the future of robotic surgery? Here's a comparative analysis to help you make a smart choice for 2025.
MDTPositive Net Change ISRGPositive Net Change
medical medical-devices
5 Valuable Price-to-Book Stocks to Strengthen Your Portfolio
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and PSFE are some such stocks.
PFEPositive Net Change CVSPositive Net Change CNCNegative Net Change STNEPositive Net Change PSFEPositive Net Change
business-services computers medical-devices pharmaceuticals
Bruker Stock to Gain From the Launch of MOVE-T Liquid Dairy Analyzer
by Zacks Equity Research
BRKR unveils the MOVE-T analyzer to boost quality and efficiency in the dairy industry, setting new standards for precision and reliability.
PBHNegative Net Change BRKRNegative Net Change PAHCPositive Net Change HIMSPositive Net Change
medical medical-devices
Is Bio-Techne Stock the Right Pick for Your Portfolio Now?
by Zacks Equity Research
TECH is gaining ground in cell and gene therapy, and with Ella, while navigating macro hurdles. Is it the right fit for your portfolio today?
PBHNegative Net Change TECHNegative Net Change PAHCPositive Net Change INSPNegative Net Change
medical medical-devices
Hims & Hers Stock Falls Despite the Latest Wegovy Availability Offer
by Zacks Equity Research
HIMS launches six-month Wegovy access at $549/month, aiming to expand affordable obesity care with holistic weight loss solutions.
CORPositive Net Change HQYPositive Net Change ITGRNegative Net Change HIMSPositive Net Change
medical medical-devices
NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial
by Zacks Equity Research
NeuroPace reports promising one-year results from its NAUTILUS trial, showcasing the RNS System's effectiveness in treating idiopathic generalized epilepsy with sustained seizure reduction.
ANGOPositive Net Change CVSPositive Net Change ITGRNegative Net Change NPCENegative Net Change
medical medical-devices